OncLive TV

Dr. O’Malley on the Utility of Chemoimmunotherapy in Ovarian Cancer

August 16th 2021

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Dr. Khong on the Importance of BRCA Testing in Breast Cancer

August 16th 2021

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer. 

Dr. Miller on the Characteristics of Clonal Hematopoiesis

August 16th 2021

Peter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.

Dr. Abida on the Limitations of PARP Inhibitors in Prostate Cancer

August 16th 2021

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

Dr. Martin on the Importance of Designing Clinical Trials for Real-World Utility in MCL

August 16th 2021

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Dr. Kumar on Navigating CAR T-Cell Therapy–Related Toxicities in MCL

August 13th 2021

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.

Dr. Danilov on the Efficacy of the Combination Zandelisib and Zanubrutinib in R/R B-Cell Malignancies

August 13th 2021

Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

August 13th 2021

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Dr. Basho on the Emergence of Bispecific Antibodies in HER2+ Breast Cancer

August 13th 2021

Reva K. Basho, MD, discusses the emergence of bispecific antibodies in HER2-positive breast cancer.

Dr. Sekeres on the Goal of Transfusion Independence in Higher-Risk MDS

August 12th 2021

Mikkael A. Sekeres, MD, discusses the goal of transfusion independence in higher-risk myelodysplastic syndromes.

Dr. Jamieson on the Importance of Treating at Diagnosis in Myelofibrosis

August 12th 2021

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Dr. Sam on Therapeutic Developments in Metastatic HER2+ Breast Cancer

August 12th 2021

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

Dr. Chase on the Importance of Genetic Testing for BRCA Mutations in Ovarian Cancer

August 12th 2021

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Dr. Extermann on the Utility of Trastuzumab Monotherapy in HER2+ Breast Cancer

August 11th 2021

Martine Extermann, MD, PhD, discusses the utility of single-agent trastuzumab in HER2-positive breast cancer.

Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPC

August 11th 2021

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Thompson on the Evolving Role of MRD Testing in CLL

August 11th 2021

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Dr. Kahl on the Emergence of Antibody-Drug Conjugates in Lymphoma

August 11th 2021

Brad S. Kahl, MD, discusses the emergence of antibody-drug conjugates in lymphoma.

Dr. Vose on Future Research Efforts With CAR T-Cell Therapy in Lymphoma

August 11th 2021

Julie M. Vose, MD, MBA, discusses future research efforts with CAR T-cell therapy in lymphoma.

Dr. Moskowitz on the Challenges of Intensifying Treatment in Hodgkin Lymphoma

August 11th 2021

Alison J. Moskowitz, MD, discusses the challenges of intensifying treatment in Hodgkin lymphoma.

Dr. Ansell on Incorporating Immunotherapies Beyond CAR T-Cell Therapy in NHL

August 11th 2021

Stephen M. Ansell, MD, PhD, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.